非药物干预对认知障碍患者的影响:系统性审查和网络元分析
Junjie Peng1, Renjie Chang2, Xinghong Wei1
1School of Nursing, Yunnan University of Chinese Medicine, Kunming, 650500, China.
BMC public health
|October 1, 2024
概括
营养支持是改善认知虚弱和认知功能最有效的. 运动和认知训练也显著提高了认知障碍患者的身体表现和运动能力.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
背景情况:
- 认知障碍和虚弱是老年人群的重大健康问题.
- 非药物干预为管理这些疾病提供了一个有希望的途径.
- 需要基于证据的建议,为最佳干预措施做出建议.
研究的目的:
- 系统地评估和排名各种非药物干预对认知障碍患者的有效性.
- 通过网络元分析,综合随机对照试验 (RCT) 的发现.
主要方法:
- 从2000年到2024年2月,对多个数据库 (PubMed,Cochrane图书馆,EMbase,科学网,CNKI,VIP,WANFANG,SinoMed) 进行系统搜索.
- 包括聚焦于认知脆弱的非药物干预的RCT.
- 使用Stata15和R4.3.1软件进行网络元分析,以身体和认知功能为主要结果.
主要成果:
- 分析了19个涉及1738名患者的RCT.
- 营养支持在改善虚弱和认知功能得分方面表现出最大的有效性.
- 综合有氧和阻力训练在增强握力方面表现出色.
- 认知训练被证明是最有效的改善定时启动和启动 (TUG) 测试成绩.
- 高速阻力训练在提高步行速度方面表现优越.
结论:
- 营养支持是改善身体虚弱和认知衰退的主要非药物干预措施.
- 运动 (有氧运动,阻力运动) 和认知训练干预措施显著提高身体表现,包括握力和运动能力.
- 这一分析提供了对管理认知虚弱的非药理学策略的排名比较.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
106
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106
Cognitive Development During Adulthood
65
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
65
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


